Posters

Five-year endotelial cell loss after implantation with phakic anterior cham-ber lens, Artiflex®

Poster Details

First Author: M.Royo Sans SPAIN

Co Author(s):    A. Jiménez López                    

Abstract Details

Purpose:

To evaluate the long-term changes in enthotelian cell density (ECD) and morphology after the implantation of an anterior chamber phakic lens to asses the safety of the surgery tecnique.

Setting:

Department of Ophthalmology, Hospital San Rafael, Madrid, Spain.

Methods:

Fifty-five eyes of 31 patients implanted with Artiflex® Myopia and Artiflex® Toric (Ophtec BV, Groningen, The The Netherlands) anterior chamber phakic lens since 2008 to 2015. Main outcome measures were endotelial cell loss, percentage of corneal endotelial polimegatism and pleomorphism measure by specular micros-copy (EM-3000, Tomey®, Japan) before surgery, 5 weeks, 12 months and 5 years after pakic intraocular lens implantation.

Results:

Chronic endothelial loss showed an anual decreasing of 26.8 cd/mm2 (p<0.005) from after surgery to 5 years before Artiflex® implant. The number of endo-thelial cells after surgery was 2880,46 ± 198,74 cd/mm2. Total chronic endotelial lost from baseline to 5 years postoperatively was 4.65% (0.93% each year). A 2.23% reduction was observed during the first year when endothelial pleo-morphism was examined. No significant changes in the size of endothelial cells have been observed during the period studied (30,2% constantly).

Conclusions:

The chronic loss of endotelial cells was around 4.65% over a period of 5 years in eyes implanted with Artiflex according to the results of physiological lost of en-dothelial cells. No significant changes in the shape and size of endothelial cells are observed. These data demonstrate that the Artiflex® anterior chamber implant for the correction of myopia and astigmatism is a safe procedure and that it does not produce a reduction of endothelial cells greater than physiological one after surgery.

Financial Disclosure:

None